Special Issue

Navigating the Evolving Landscape of Gynecology: From Diagnosis to Treatment

Message from the Guest Editors

The landscape of gynecological oncology has been transformed by advancements in precision medicine and immunotherapy, ushering in a new era of personalized cancer care. From targeted molecular therapies to novel immunomodulatory agents, these groundbreaking treatments hold promise for improved outcomes and enhanced quality of life for women with gynecological malignancies.In this update on gynecology, we embark on a comprehensive journey from diagnosis to treatment, exploring the latest advancements that shape the landscape of women's health care. By delving into the intricate interplay between cutting-edge diagnostics and innovative therapeutic modalities, we aim to provide insights into the evolving landscape of gynecological care and its profound impact on patient outcomes and well-being. Therefore, original articles, reviews, and meta-analyses are welcome in this Special Issue.

Guest Editors

Dr. Ferdinando Antonio Gulino

Department of Obstetrics and Gynaecology, Azienda di Rilievo Nazionale e di Alta Specializzazione (ARNAS) Garibaldi Nesima, 95124 Catania, Italy

Dr. Stefano Cianci

Department of Obstetrics and Gynecology, University of Messina, 98122 Messina, Italy

Deadline for manuscript submissions

15 July 2025

About the Journal

Message from the Editorial Board

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editors-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).